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The human RNA methyltransferase BCDIN3D is overexpressed in breast cancer cells and involved in cellular 
invasion and poor prognosis of breast cancer. Several years ago, BCDIN3D was reported to dimethylate the 
5'-monophosphate of specific precursor miRNAs (pre-miRNAs), such as the tumor suppressor miR145. 
Dimethylation of the 5'-monophosphate of the pre-miRNA negatively regulates the subsequent processing by 
Dicer in vitro, and results in the downregulated expression of the mature form of the miRNA. The depletion of 
BCDIN3D also reportedly results in the suppression of the tumorigenic phenotype of breast cancer cells. Thus, 
these findings suggested that BCDIN3D promotes the cellular invasion of breast cancer cells, by downregulating 
the expression of tumor suppressor miRNAs via the dimethylation of the 5'-monophosphate of the corresponding 
pre-miRNAs. Recently, we found that cytoplasmic tRNAHis is actually the primary target of human BCDIN3D, 
rather than pre-miR145. BCDIN3D monomethylates the 5'-phosphate of cytoplasmic tRNAHis much more 
efficiently than that of pre-miRNA in vitro, and is responsible for the monomethylation of the 5'-phosphate of 
cytoplasmic tRNAHis in vivo. BCDIN3D recognizes the eight-nucleotide long extended acceptor helix with the 
G-1-A73 mis-pair at the top of the acceptor stem of tRNAHis, which are exceptional features among cytoplasmic
tRNA species. These results not only reveal the primary target of BCDIN3D, which is overexpressed in breast
cancer cells, but also highlight the possible involvement of the 5'-phosphomethylation of tRNA and/or tRNA in
the tumorigenesis of breast cancer cells, beyond its established function in protein synthesis.
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BCDIN3D, the BCDIN3 (bicoid-interacting protein 3) 
Domain containing protein, contains an 
S-(5'-adenosyl)-L-methionine (AdoMet) binding motif, and 
is homologous to a conserved family of eukaryotic protein 
methyltransferases acting on RNA-binding proteins [1]. 
BCDIN3D is conserved from worm to human [2]. The 
BCDIN3D mRNA is overexpressed in human breast cancer 
cells, and the elevated expression of BCDIN3D is related to 
poor prognosis in breast cancer [3]. The biological roles and 
functions of BCDIN3D are poorly understood, and the 
molecular basis of the involvement of BCDIN3D in the 
tumorigenic phenotype of breast cancer has remained 
enigmatic. 
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Several years ago, it was reported that BCDIN3D 
dimethylates the 5'-monophosphate of specific precursor 
micro RNAs (pre-miRNAs), such as the tumor suppressors 
miR145 and miR23b [2, 4-7]. Dimethylation of the 
5'-monophosphate of the pre-miRNA negatively regulates the 
subsequent processing by Dicer in vitro, and results in the 
downregulated expression of the mature miRNA. The 
downregulation of tumor suppressor miRNAs could be 
related to the tumorigenic phenotype of breast cancer cells. 
Indeed, it was also reported that the depletion of BCDIN3D 
resulted in the suppression of the tumorigenic phenotype of 
MDA-MB231 breast cancer cells [2]. Therefore, it was 
suggested that BCDIN3D promotes the cellular invasion of 
breast cancer cells, by negatively regulating the expression of 
tumor suppressor miRNAs. However, the mechanisms by 
which BCDIN3D recognizes only a specific group of 
pre-miRNAs and negatively regulates the expression of 
mature miRNAs in breast cancer cells are not well 
understood. 
With an aim to identify other possible RNA substrates that 
are methylated by BCDIN3D, and to clarify the mechanism 
by which BCDIN3D recognizes specific RNAs and controls 
their expression, we analyzed BCDIN3D-binding RNAs in 
human HEK293T cells [8]. When BCDIN3D, expressed in 
HEK293T cells, was purified from the cell extract, we 
noticed that a distinct, seventy-eighty nucleotide RNA 
molecule was co-purified with the BCDIN3D protein. Since 
the nucleotide sequences of cytoplasmic tRNAHis from 
human and fruit fly were reported to have a 
5'-monomethylphosphate [9, 10], we assumed that the RNA 
might be cytoplasmic tRNAHis. The analysis of the RNA 
co-purified with BCDIN3D, by RT-PCR and DNA 
sequencing of RT-PCR products, confirmed that cytoplasmic 
tRNAHis co-purified with BCDIN3D from the cell extracts, 
but other tRNAs, such as tRNAPhe, did not. A subsequent 
detailed analysis of the RNaseT1 and RNaseA-digested 
fragments of the RNA by LC-mass spectrometry [11-13] 
clearly demonstrated that the RNA is cytoplasmic tRNAHis. 
More importantly, the 5'-monophosphate of cytoplasmic 
tRNAHis was monomethylated, but not dimethylated. The 
5'-monophosphate of cytoplasmic tRNAHis, co-purified with 
BCDIN3D from extracts of HEK293T cells overexpressing 
BCDIN3D, is fully methylated. Thus, we asked whether the 
5'-phosphate of cytoplasmic tRNAHis is methylated under 
normal physiological conditions. Cytoplasmic tRNAHis was 
purified from HEK293T cells and analyzed by LC-mass 
spectrometry, which revealed that the 5'-monophosphate of 
tRNAHis is fully monomethylated under normal physiological 
conditions in HEK293T cells. 
These results prompted us to examine whether BCDIN3D 
could methylate the 5'-monophosphate of cytoplasmic 
tRNAHis. The recombinant human BCDIN3D protein was 
expressed in Escherichia coli, and its enzymatic activity was 
examined using the human cytoplasmic tRNAHis transcript as 
the substrate and SAM [S-(5'-adenosyl)-L-methionine] as the 
methyl-group donor in vitro. The results showed that the 
cytoplasmic tRNAHis transcript is efficiently methylated by 
BCDIN3D in vitro. However, unexpectedly, the human 
miR145 precursor transcript, which was previously shown to 
be dimethylated by BCDIN3D, is hardly methylated under 
the same conditions. The reaction products were further 
analyzed by LC-mass spectrometry, and the results 
confirmed that BCDIN3D monomethylates the 
5'-monophosphate of cytoplasmic tRNAHis much more 
efficiently than the pre-miR145 transcript. Moreover, 
BCDIN3D could not dimethylate either tRNAHis or 
pre-miR145 in vitro. The steady state kinetics of the 
methylation of these RNA substrates also confirmed that 
cytoplasmic tRNAHis is a better substrate than pre-miR145, 
by over two to three orders of magnitude. 
To explore whether BCDIN3D is responsible for the 
monomethylation of the 5'-monophosphate of cytoplasmic 
tRNAHis in vivo, BCDIN3D-knockdown cells were 
established from HEK293T cells by CRISPR/Cas9 editing 
[14-16]. The growth rate of the BCDIN3D knockdown cells 
was slightly slower than that of the parental HEK293T cells. 
The cytoplasmic tRNAHis isolated from the BCDIN3D 
knockdown cells lacked the methyl moiety at its 
5'-monophosphate. The exogenous expression of BCDIN3D 
in the BCDIN3D knockdown cells restored the 
5'-monomethylphosphate modification of the cytoplasmic 
tRNAHis. Thus, BCDIN3D catalyzes the monomethylation of 
the 5'-monophosphate of cytoplasmic tRNAHis in HEK293T 
cells, under normal physiological conditions. Moreover, 
except for cytoplasmic tRNAHis, no other RNAs in 
BCDIN3D knockdown cells are significantly methylated by 
recombinant BCDIN3D in vitro. Together with the results 
obtained in the in vitro methylation assay, using recombinant 
BCDIN3D and the tRNAHis transcript, it is most likely that 
the primary target of BCDIN3D is cytoplasmic tRNAHis 
rather than pre-miRNAs, and BCDIN3D has a 
monomethylation activity acting on the 5'-phosphate of RNA 
[8]. Under specific conditions or in certain biological 
processes, the pre-miRNA might be methylated efficiently, 
and unknown regulatory factors specific to breast cancer 
cells might enhance the efficient pre-miRNA (di)methylation 
process in vivo. The in vivo mechanism of the dimethylation 
of the 5'-monophosphate of specific pre-miRNAs, such as 
pre-miR145, in breast cancer cells awaits further studies.  
How does BCDIN3D specifically recognize cytoplasmic 
tRNAHis? Human cytoplasmic tRNAHis is matured through 
unique processes [17 ,  18 ]. After transcription by RNA 
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polymerase-III, the 5'-leader and 3'-tail sequences of the 
precursor tRNAHis are removed. Subsequently, a single 
guanosine residue (G) is attached to the 5'-end (at position -1; 
G-1) by a tRNAHis-specific guanylyltransferase (Thg1) [17, 19,
20] and the CCA is added at the 3'-end (positions 74-76) [21].
As a result, the mature cytoplasmic tRNAHis has an
eight-nucleotide long acceptor helix with G-1-A73 mis-pairing
at the top of the helix, while other cytoplasmic tRNAs have
seven-nucleotide long acceptor helices. Analyses of the in
vitro steady state kinetics of methylation of mutant
cytoplasmic tRNAHis transcripts by recombinant BCDIN3D
revealed that BCIDN3D recognizes G-1, and the
eight-nucleotide long extended acceptor helix with G-1-A73
mis-pairing at the top of the acceptor stem of cytoplasmic
tRNAHis. Thus, BCDIN3D recognizes the unique features of
cytoplasmic tRNAHis, and discriminates cytoplasmic tRNAHis
from other tRNA species [8].
The function of the 5'-monomethylphosphate of 
cytoplasmic tRNAHis has remained elusive. While the 
5'-monomethylphosphate of cytoplasmic tRNAHis lowers the 
affinity of tRNAHis toward histidyl-tRNA synthetase (HRS), 
as expected from the complex structure of bacterial HRS 
with tRNAHis [22], the overall aminoacylation efficiency is not 
affected by the modification. The steady-state levels of 
cytoplasmic tRNAHis in parental HEK293T and 
BCDIN3D-knockdown cells are not significantly different. 
Furthermore, the stabilities of cytoplasmic tRNAHis from 
HEK293T and BCDIN3D-knockdown cells after the 
treatment of the cells with actinomycin-D were not 
significantly different. However, the 
5'-monomethylmonophosphate protects cytoplasmic tRNAHis 
from degradation in vitro, in cytoplasmic cell extracts. Thus, 
BCDIN3D could act as a cytoplasmic tRNAHis-specific 
5'-methylphosphate capping enzyme, and the methylation of 
the 5'-monophosphate of cytoplasmic tRNAHis might be 
Figure 1. A possible link between tRNA methylation and the tumorigenic phenotype of breast cancer. BCDIN3D is 
overexpressed in breast cancer cells, and the elevated expression is related to the tumorigenic phenotype and poor 
prognosis of breast cancer. Cytoplasmic tRNAHis is now found to be the primary target of BCDIN3D. The 5’-monophosphate 
of cytoplasmic tRNAHis is monomethylated by BCDIN3D. The modification of tRNAHis and/or tRNAHis itself might be involved 
in the tumorigenic phenotype of breast cancer, beyond its established function in protein synthesis. 
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involved in increasing its stability under specific conditions 
or in certain biological processes. 
The elucidation of the involvement of the 
5'-monophosphate methylation of cytoplasmic tRNAHis in the 
tumorigenic phenotype of breast cancer is challenging 
(Figure 1). tRNAs are classical non-coding RNAs, and their 
established functions, as adaptor molecules between genetic 
codes and amino acids, have been well studied for more than 
sixty years. However, besides their roles as adaptor 
molecules in protein synthesis, tRNAs are involved in 
various biological processes in cells [23-25]. Recent studies 
have shown that the expression level of initiator tRNAMet is 
elevated in breast cancer cells [26]. The upregulation of 
specific tRNAs, such as tRNAGluUUC and tRNAArgCCG, 
reportedly stabilizes mRNAs containing the corresponding 
codons and enhances translation in highly metastatic breast 
cancer cells [27]. However, the steady state level of 
cytoplasmic tRNAHis is not affected by the knockdown of 
BCDIN3D in HEK293T cells. Thus, it is unlikely that the 
methylation of the 5'-monophosphate of cytoplasmic tRNAHis 
increases the translation of specific mRNAs, although it 
should be examined in the future. Recent studies also have 
provided evidence that small RNA fragments derived from 
tRNAs - tRNA fragments (tRFs) - participate in various 
cellular functions [23-25]. These tRFs are often produced under 
stress conditions [28-32]. In breast and prostate cancers, 
specific tRNAs, such as cytoplasmic tRNALys and tRNAHis, 
are cleaved by angiogenin, and the tRNA halves are 
abundantly expressed in a sex hormone-dependent manner 
[33]. These tRNA halves have also been shown to promote the 
proliferation of breast and prostate cancer cells, by an as yet 
unknown mechanism. In human and mouse cells, 3'- or 5'- 
terminal tRFs (3'-tRF or 5'-tRF) reportedly accumulate in 
cells in an asymmetric manner, and these tRFs associate with 
Ago2 [34]. These tRFs probably act as typical miRNAs. tRNA 
modifications, such as 5-methyl cytidine, are associated with 
the stress induced cleavage of tRNA molecules and the 
production of tRFs in cells [31]. The 5'-monomethylation of 
the 5'-monophosphate of tRNAHis may control the expression 
of the tRNA halves and/or tRFs derived from tRNAHis in 
breast cancer cells or under specific biological or stress 
conditions. Future work will clarify whether the methylation 
of the 5'-phosphate of tRNAHis by BCDIN3D is involved in 
the tumorigenic phenotype of breast cancer and other 
cancers. 
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